Nkarta, Inc. Appoints Alyssa Levin as Chief Business Officer

Nkarta, Inc. announced the appointment of Alyssa Levin as Chief Financial and Business Officer. Ms. Levin joins Nkarta from Viacyte, a biotechnology company developing stem cell therapy for diabetes, where she oversaw financial strategy and planning as Chief Financial Officer and led the company’s successful merger with Vertex Pharmaceuticals in 2022. Previously, Ms. Levin was Chief Financial Officer and Senior Vice President of Operations at Tentarix Biotherapeutics from 2020 to 2022, and Chief Financial Officer at Bird Rock Bio, Inc. from 2019 to 2020.

Ms. Levin’s experience also includes financial roles at PricewaterhouseCoopers and The Siegfried Group where she advised clients on IPO and M&A processes. She began her career at PricewaterhouseCoopers in 2009. Immediately prior to her start as Chief Financial and Business Officer of Nkarta, Ms. Levin served as a consultant to the company.

Ms. Levin received a B.A. in Psychology and Economics from the University of British Columbia, and a Masters in Professional Accounting from the Edwards School of Business at the University of Saskatchewan. She is also a Chartered Professional Accountant (Canada).